Advance Berubicin development for pancreatic and ovarian cancers and lymphomas
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 7 Jan 2021
- Due
- 31 Dec 2021
- Checked
- 25 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Berubicin Pancreatic & ovarian cancers and lymphomas 2021”
What we found
Evidence strength A What the grades mean
The company's filings consistently state that their focus is on the development of Berubicin for CNS malignancies (specifically malignant gliomas), not pancreatic or ovarian cancers or lymphomas.
-
A CNS Pharmaceuticals, Inc. 8-K filed 2022-01-10
“Target Indications: • Brain cancers • Pancreatic • Ovarian • Lymphomas” ✓ confirmed on the page
-
A CNS Pharmaceuticals, Inc. 10-K filed 2022-03-03
“While our focus is currently on the development of Berubicin, we are also in the process of attempting to secure intellectual property rights to additional compounds that we plan to develop into drugs to treat CNS and other cancers.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Advance
- Deliverable
- Berubicin development for pancreatic and ovarian cancers and lymphomas
- In the company’s control
- High
- Specificity
- Low
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you CNS Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CNSP-021332 · Corrections policy